[Traumatic optic neuropathy: a review of the literature in the light of personal experiences].
BACKGROUND
Therapy of traumatic optic neuropathy (TON) is still discussed controversially. Studies of medical treatment and surgical decompression of the nerve could not find any correlation between therapy and result. Today's knowledge of the treatment in TON is to be analyzed by the latest results in the literature, supplemented by personal experiences with our own patients, who underwent a combination of corticosteroids and surgical decompression.


METHODS
The study group consisted of 9 patients at the age of 13-58 years. 8 patients suffered from a cranial trauma, 1 patient had sinus surgery, which resulted in an indirect damage of the optic nerve. Pretherapeutically, 5 patients had residual vision, 4 patients were blind. A fracture line through the optic canal in the CT-scan was seen in 6 cases. Decompression was performed within 24 hours in 3 cases; in the worst 3 cases it took up to 8 days. In 8 patients the intervention was performed via an endonasal, microscopic-endoscopic approach, once it was done transfacially. Simultaneously, high-dose corticosteroids were administered.


RESULTS
All patients with a residual vision before therapy showed an improvement of their visual acuity: In the best case visual acuity changed from perception of light to 0.8. All patients with posttraumatic blindness remained blind after therapy.


CONCLUSIONS
A surgical decompression may be considered in patients with residual vision. Referring to the latest data in the literature endonasal, microscopic-endoscopic decompression is then to be combined with simultaneous application of high-dose corticosteroids. In our opinion, a mere wait-and-see strategy completely without any treatment can hardly be recommended.
Klinikum Darmstadt GmbH, Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf-, Hals- und plastische Gesichtschirurgie, Darmstadt. lngo.Ott@Klinikum-Darmstadt.de
I
I
Ott
K
K
Schwager
R
R
Hagen
G
G
Baier
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001766:Blindness / Q000209:etiology; D003131:Combined Modality Therapy; D019299:Decompression, Surgical; D004305:Dose-Response Relationship, Drug; D004724:Endoscopy; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008866:Microsurgery; D008875:Middle Aged; D020221:Optic Nerve Injuries / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012887:Skull Fractures / Q000150:complications; D013100:Sphenoid Bone / Q000293:injuries; D015354:Vision, Low / Q000209:etiology; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D008775:Methylprednisolone